Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores ...

Alan Alda’s first symptoms of Parkinson’s disease weren’t the typical tremors, stiffness or slow movement. It was throwing a ...

Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...

Alan Alda has lived publicly with Parkinson’s disease for eight years, but at 90 he still refuses to let the diagnosis become ...

Alan Alda says the first Parkinson’s symptom that he experienced ‘was not that well-known’ at the time, adding that he had ...

Actor Alan Alda was diagnosed with Parkinson’s disease in 2015. The M*A*S*H and West Wing star was also diagnosed with face blindness last year. Now, he has revealed the first symptom of Parkinson’s ...

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as ...

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Alan Alda Opens Up About Parkinson's Diagnosis: I Can't Wish It Away ...

Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 International ...

Lundbeck to present progress across its movement disorders pipeline with data in MSA, Parkinson’s disease at MDS 2026: Valby, Denmark Monday, October 5, 2026, 17:00 Hrs [IST] H.